Member Info for Vinylspinner

Morning,

👀’s on the prize.

🎯

Here’s to a solid day, and Dennis will be presenting this evening to our friends in the US. 🇺🇸

Great time, and entry point(the early bird, catches the worm)

The future is bright.

Nothing has changed we’re just more undervalued than yesterday.

Also a great buying opp for any folks sat on the sidelines wanting a slice of the Solvonis cake.

Take care all.

‘Hot money’ 😂

Best to keep emotions in track.

My interpretation, is simple market mechanics, some biotech investors ‘hot mine’ being moved around into hot stocks of the week. They will probably try to make some dollar, and come back here and try to have more shares than when they sold today.

I work full time, so trading is not my game but good luck to those that do.

Nothing has changed.

We still have a stellar BOD, phase 3 trials, DP USA presentation, lead candidate due by the end of July, still talking to 6 interested partners.

Still have the answers to a global huge unmet need.

No point panicking everytime it retraces, just be pleased you found SVNS and hold for gold.

I’m very relaxed knowing I’m focused on what the share price will be in the future not these intraday ups and downs.

All good in the hood guys & gals 🎯1.6p

Focus. 🧘‍♂️

Join the fluffin dots ….💰…🎯….🔔….🔵…..💰

Tricky

Basically DP knows how to do a deal 🔔

Solvonis Therapeutics plc Congratulates Chair Dennis Purcell on $1.9B IGI–AbbVie Deal

Congratulations to our Chair, Dennis Purcell, on the announcement of a landmark $1.9 billion global licensing deal between IGI (Ichnos Glenmark Innovation) and AbbVie.

Under the terms of the agreement, AbbVie has secured exclusive rights to ISB 2001, a first-in-class CD38×BCMA×CD3 trispecific antibody, across North America, Europe, Japan, and Greater China.

Deal highlights:

💰 $700 million upfront payment

📈 Up to $1.225 billion in development, regulatory, and commercial milestones

📊 Tiered, double-digit royalties on future net sales

Dennis Purcell serves as a Non-Executive Director at IGI and brings unmatched experience in scaling breakthrough science across global markets. This deal is further testament to the calibre of strategic leadership Dennis brings to the sector — and to Solvonis Therapeutics plc.

We're proud to have him lead our Board as we advance our differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

Well done Dennis.

https://www.linkedin.com/posts/solvonis_abbvie-and-ichnos-glenmark-innovation-igi-activity-7350434397713588224-nNTe?utm_source=share&utm_medium=member_ios&rcm=ACoAAAPXVmkB76Y7Nuylz189l6vufJwTsraV4qU

🎯1.6p

Good morning team.

The term I want to see in an RNS

“Partnership”

They will be near term.

The BOD are executing, doing what they said they would do, just generally working hard on our behalf and who’d bet against them successfully delivering.

Here’s to another day closer to getting our Andy’s early retirement 🙏🏻📈🎯🔔🔔🔔🔔🔔’s on.

🔵

Great interview with AT.

I maintain my position here.

Undervalued with 🔔’s on.

We go again this week. Blue days ahead, Blue weeks ahead. Blue months ahead.

Blue is the colour🇬🇧

Blue is the color 🇺🇸

We have the solutions to massive unmet needs & we also have a quite remarkable team at the helm of this biotech minnow.

The sky is the limit in my humble opinion. 📈

Lovely. Cashed up and ready to rock n roll.

Perfectly acceptable to me to raise at a premium when you have specific uses to grow the company.

BOD have skin in the game, so dilution albeit small also costs them.

The thing with SVNS it’s not a lifestyle raise. These are world class professionals wanting to make real world difference creating a lasting legacy and if they do. The share price will do to.

Excellent

AA..

The rationalè is, that we/I believe it’s Oberon who have been taking profits, and is the seller of the 5 million chunks that have been suppressing our share price by snuffing out gains due to new investors buying.

They can only sell once, so if they pause/stop/or run out of shares to sell, when we get a positive RNS from Solvonis, the share price will be able to go up without being held back.

Hope that helps. Just my take.

Oberon be gone.

Let’s get back to Blue days again.

🔔’s on! 🔵

Super week here.

Huge interest and I’m sure on many more investors watchlists.

Very healthy consolidation today, chunky new money, some old money getting off at there stop, and everything in between.

Fascinating biotech story unfolding here, and I can’t wait for the story to unfold.

Wishing everyone a healthy and relaxing weekend.

Catch you all Monday.

VS

Total wealth.

Exactly. Look at the quality & network of our BOD.

Acquiring Awaken under the umbrella of Solvonis(new biotech company) wasn’t a small/short undertaking.

It was validation for the huge potential they see in phase 2 & 3 trial data, and all part of the master plan to wrap this in a main market U.K. listing.

Serious player

Stellar board with skin in the game

And a serious contender to be the best performing share of 2025, 2026 & 2027.

Eyes on capital growth. Ignore the hour to hour market mechanics, rises & retraces.

Stop dreaming and start believing you’ve found the ONE.

I’ve just emailed Karl Keegan enquiring as to the publication being available to us mere PI’s.

Nudge nudge Karl, release the Kraken 🎯📈🔔

Happy Friday esteemed PI investors & co.

Must be close to an announcement soon.

Would really cement the foundational modest rise we’ve had over the last few trading sessions.

May we also get an RNS ref the link to the public publication of the Singer capital broker note ref the 1.6p share price valuation.

C’mon Solvonis, let’s get this biotech minnow swimming with the big boys! 🦈

Thanks for the peer review data LF.

Demonstrates what a fantastic position Solvonis is in, and what a fantastic job our BOD have done and are doing in this space.

Sync this with the Singer Capital " P s y c h i n g u p f o r s u c c e s s" authored by Dr. Karl Keegan, Head

of Life Sciences Research at Singers advising a value of 1.6p per share and we can clearly see that we are indeed hugely undervalued.

We are now at least gaining solid traction, new investors, and a lot more eyes on researching this company. There will be many on the sidelines, but for how much longer given the clear potential here providing therapeutic solutions to a global unmet need.

This company is the real deal, just look at the quality of the BOD. They could literally enhance any biotech company on the planet but they chose Solvonis and also have put their own skin in the game.

Buy(oh I’ve bought) Hold(oh I’m holding Leslie!) go to work(boy do I work, first year of my own business) and watch this company go and grow from strength to strength.

It’s the Nutt’s!

All in my humble opinion of course.

Happy Thursday guys and gals, and Happy Friday to our Tricky 😉📈🔔🔔🔔🔔🔔

Https://www.linkedin.com/posts/solvonis_solvonis-svn001-severeaud-activity-7345784178782748672-GDt5?utm_source=share&utm_medium=member_ios&rcm=ACoAAAPXVmkB76Y7Nuylz189l6vufJwTsraV4qU

Let’s head up on the highway! 🎸📈🔔🔔🔔😇🤘🏻